Shoulder Innovations is a commercial-stage medical technology company focused on the shoulder surgical care market. The company offers advanced implant systems for shoulder arthroplasty, including anatomic and reverse total shoulder arthroplasty systems featuring InSet Glenoid and humeral stem technologies. Its product ecosystem includes the ProVoyance preoperative planning technology, which uses artificial intelligence and machine learning to convert CT imaging into 3D renderings for surgical planning, and an efficient instrument system designed to support procedures with minimal trays. The company serves surgeons and healthcare facilities, including ambulatory surgery centers, in the United States and internationally. Shoulder Innovations has established an exclusive partnership with ALM Ortho for complex shoulder reconstruction solutions and has received FDA clearance for its N-22 Humeral Head and ProVoyance platform.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage ir.shoulderinnovations.com
Sector Healthcare IR page ir.shoulderinnovations.com
Tags
shoulder arthroplasty, orthopedic implants, preoperative planning, ai medical imaging, surgical instruments, anatomic total shoulder arthroplasty, reverse total shoulder arthroplasty, InSet Glenoid, InSet humeral stem, ProVoyance, InSet Go, N-22 Humeral Head, ALM Ortho
Press page ir.shoulderinnovations.com/news-events/news-releases

Metrics

Valuation  
Market cap $ 395.43M
Market cap (USD) $ 395.43M
P/E -4.06
PEG —
P/BV 3.34
P/S 8.36
P/OCF -13.82
P/FCF -10.98
Dividend yield —
Turnover / mcap —
Returns  
ROE -28.7%
ROI -25.9%
ROIC -12.7%
Profit margin -85.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 12.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 39
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023
Revenue 47.317M 31.623M 19.274M
Net profit -40.359M -15.619M -12.655M
Free cash flow -36.02M -18.158M -15.892M

Figure FY 2025 FY 2024 FY 2023
Share price 14.3 — —
P/FCF -8.19 — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 5.12M 8.27M
↳ YoY growth +61.4%
Borrowings, non-current (USD) — 14.7M 14.9M
Lease liabilities (USD) — 47,000 62,000
Cash and deposits (USD) 6.24M 6.12M 26.9M
Intangible assets (USD) — 400,000 100,000
Right-of-use assets (USD) — 68,000 110,000
Net debt (borrowings + leases - cash) (USD) — 8.58M -11.9M
Cash flow detail
Operating cash flow (USD) — -14.1M -28.6M
Purchases of property, plant and equipment (USD) — -4.02M -7.41M
Change in receivables (cash effect) (USD) — -575,000 -3.3M
Change in inventories (cash effect) (USD) — -4.03M -7.64M
Change in payables (cash effect) (USD) — 3.12M 3.37M
Interest paid (cash effect) (USD) — -1.79M -1.69M
Share-based compensation (USD) — 754,000 996,000
Operating cash flow before change in receivables (USD) — -13.6M -25.3M
Free cash flow (OCF - PPE - intangibles) (USD) — -18.2M -36M
Income detail
Research and development expense (USD) — 4.49M 7.73M
Total comprehensive income (USD) — -15.8M -40.4M
Comprehensive income to owners (USD) — -15.8M -40.4M
Provision for credit losses (USD) — 146,000 153,000
Credit cost ratio (credit losses / average receivables) (%) — — 2.3%
Reported Sep 9, 2025 Mar 10, 2026 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

52% Year-to-Date 2026 Revenue Growth

Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter Financial Highlights

•Generated net revenue of $16.2 million in the third quarter, a 38% increase over the third quarter of 2025

•Achieved gross margin of 78.5% for the third quarter compared to 76.2% for the third quarter of 2025

•Increased average selling price of our implant systems to $7,616 in the third quarter, a 2% increase over the third quarter of 2025

•Increased full year 2026 net revenue guidance to $68 million to $70 million, representing growth of approximately 44% to 48% over full year 2025 net revenue

Recent Business Highlights

•Sold 2,126 total implant systems in the third quarter, an approximate 34% increase over the third quarter of 2025

•Completed the first surgical cases with InSet® Go, the company’s next-generation InSet® anatomic glenoid implant

•Received FDA 510(k) clearance for and initiate

October 27, 2026 4:05pm EDT Download as PDF

GRAND RAPIDS, Mich., Oct. 27, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that members of management will participate in the following upcoming investor conferences:

Shoulder Innovations company logo

**UBS Global Healthcare Conference
**Format: Fireside chat
Date: Tuesday, November 10
Fireside chat time: **3:30 PM – 4:05 PM EST
**Location: Palm Beach Gardens, FL

**Jefferies Global Healthcare Conference
**Format: Hybrid presentation & fireside chat
Date: Tuesday, November 17
Presentation time: **11:30 AM – 11:55 AM EST
**Location: London, UK

Live and archived webcasts of both events will be available in the "Investor Relations" section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/ .

**About Shoulder Innovations
**Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

October 15, 2026 4:05pm EDT Download as PDF

GRAND RAPIDS, Mich., Oct. 15, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the third quarter of 2026 after market close on Thursday, November 5, 2026.

Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on November 5, 2026. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domestic callers or (412) 902-1015 for international callers and providing access code 13762885. A live and archived webcast of the event will be available in the "Investor Relations" section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/

.

Prompts

Shoulder Innovations, Inc. (ticker SI), listed in United States.

Company History

Date Change Detail
— Different company Silvergate Capital Corp (CIK 1312109) is a different company that has used this ticker. Its filings are not shown here.

ETFs Holding Shoulder Innovations, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 13,697 $ 280.104K Nov 16, 2026